Hypoxia and cribriform growth in prostate cancer - establishing a link via MRI.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
291 patients with biopsy-confirmed PCa who underwent radical prostatectomy and pre-operative MRI was analyzed.
I · Intervention 중재 / 시술
radical prostatectomy and pre-operative MRI was analyzed
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
These findings provide further biological insights into the aggressive nature of cribriform growth architecture and highlight the potential clinical utility of non-invasive hypoxia quantification for risk stratification in prostate cancer management. [CLINICAL TRIAL NUMBER] Not applicable.
[BACKGROUND] Prostate Cancer (PCa) is a heterogeneous disease, where hypoxia and cribriform growth have been established as adverse prognostic features.
- p-value p < 0.001
APA
Fernandez Salamanca M, van Houdt PJ, et al. (2025). Hypoxia and cribriform growth in prostate cancer - establishing a link via MRI.. BMC medical imaging, 26(1), 32. https://doi.org/10.1186/s12880-025-02084-3
MLA
Fernandez Salamanca M, et al.. "Hypoxia and cribriform growth in prostate cancer - establishing a link via MRI.." BMC medical imaging, vol. 26, no. 1, 2025, pp. 32.
PMID
41366753 ↗
Abstract 한글 요약
[BACKGROUND] Prostate Cancer (PCa) is a heterogeneous disease, where hypoxia and cribriform growth have been established as adverse prognostic features. Hypoxia refers to a condition of limited oxygen concentration within the tumor microenvironment, associated with enhanced tumor aggressiveness, resistance to therapy, and poor clinical outcome. Likewise, cribriform growth has also been related to poor prognosis, though the biologic basis remains unclear. Recent pathological studies suggest that there is an association between cribriform growth and tumor hypoxia, but evidence from PCa patient studies are scarce. To fill this knowledge gap, this study aims to investigate the association between hypoxia measured by MR imaging and cribriform growth identified in whole-mount histological specimens.
[METHODS] A retrospective cohort of 291 patients with biopsy-confirmed PCa who underwent radical prostatectomy and pre-operative MRI was analyzed. Tumors were graded according to the 2019 ISUP classification, and cribriform growth presence and length were assessed on whole-mount histology. The oxygen consumption and supply based model using apparent diffusion coefficient and fractional blood volume was applied to estimate hypoxia level (HL) and hypoxia fraction (HF). Differences in HL and HF across Gleason patterns and between cribriform growth-positive and -negative tumors were assessed. Furthermore, a linear regression model was used to evaluate the association between cribriform growth and hypoxia after adjusting for confounders.
[RESULTS] Cribriform growth-positive tumors exhibited significantly higher HF values compared to cribriform growth-negative tumors (p < 0.001). Within individual cancer Grade Groups (GG), cribriform growth length was significantly associated with increased HF in pGG 3 tumors. HL values were highest in Gleason Pattern 3 (GP3) regions and lowest in cribriform growth (GP4Crib+) regions, with significant differences observed between GP3 vs. non-cribriform growth GP4 regions (p < 0.001) and GP3 vs. GP4Crib+ (p < 0.001), consistent with more hypoxia in GP4Crib+. Multivariable regression confirmed cribriform growth presence as an independent predictor of increased hypoxia fraction, even after adjusting for tumor volume and GG.
[CONCLUSIONS] This study shows an association between cribriform growth and tumor hypoxia using an MRI-based biomarker. These findings provide further biological insights into the aggressive nature of cribriform growth architecture and highlight the potential clinical utility of non-invasive hypoxia quantification for risk stratification in prostate cancer management.
[CLINICAL TRIAL NUMBER] Not applicable.
[METHODS] A retrospective cohort of 291 patients with biopsy-confirmed PCa who underwent radical prostatectomy and pre-operative MRI was analyzed. Tumors were graded according to the 2019 ISUP classification, and cribriform growth presence and length were assessed on whole-mount histology. The oxygen consumption and supply based model using apparent diffusion coefficient and fractional blood volume was applied to estimate hypoxia level (HL) and hypoxia fraction (HF). Differences in HL and HF across Gleason patterns and between cribriform growth-positive and -negative tumors were assessed. Furthermore, a linear regression model was used to evaluate the association between cribriform growth and hypoxia after adjusting for confounders.
[RESULTS] Cribriform growth-positive tumors exhibited significantly higher HF values compared to cribriform growth-negative tumors (p < 0.001). Within individual cancer Grade Groups (GG), cribriform growth length was significantly associated with increased HF in pGG 3 tumors. HL values were highest in Gleason Pattern 3 (GP3) regions and lowest in cribriform growth (GP4Crib+) regions, with significant differences observed between GP3 vs. non-cribriform growth GP4 regions (p < 0.001) and GP3 vs. GP4Crib+ (p < 0.001), consistent with more hypoxia in GP4Crib+. Multivariable regression confirmed cribriform growth presence as an independent predictor of increased hypoxia fraction, even after adjusting for tumor volume and GG.
[CONCLUSIONS] This study shows an association between cribriform growth and tumor hypoxia using an MRI-based biomarker. These findings provide further biological insights into the aggressive nature of cribriform growth architecture and highlight the potential clinical utility of non-invasive hypoxia quantification for risk stratification in prostate cancer management.
[CLINICAL TRIAL NUMBER] Not applicable.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.